ArticleEClinicalMedicine2023

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.

Zhigang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.